Get the Stockscreener App
2.19
3.95%
-0.09
Immix Biopharma Inc stock is traded at $2.19, with a volume of 173.27K.
It is down -3.95% in the last 24 hours and down -23.16% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$2.28
Open:
$2.28
24h Volume:
173.27K
Relative Volume:
0.59
Market Cap:
$63.15M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.3804
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
-3.52%
1M Performance:
-23.16%
6M Performance:
+24.43%
1Y Performance:
-0.90%
1-Day Range:
$2.17
$2.32
1-Week Range:
$2.11
$2.39
52-Week Range:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.19 | 66.32M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Stock (IMMX) Latest News
Long term hold vs stop loss in Immix Biopharma Inc.Weekly Investment Recap & Advanced Technical Signal Analysis - Newser
Using data models to predict Immix Biopharma Inc. stock movementJuly 2025 PostEarnings & Real-Time Volume Analysis - Newser
Will Immix Biopharma Inc. outperform the market2025 Market Outlook & Momentum Based Trading Ideas - Newser
Immix Biopharma Inc. stock prediction for this weekRate Cut & Reliable Breakout Forecasts - Newser
Sentiment analysis tools applied to Immix Biopharma Inc.2025 Key Highlights & High Accuracy Buy Signal Tips - Newser
Can Traders Expect Breakout From Immix Biopharma Inc. This WeekJuly 2025 Short Interest & Weekly Setup with ROI Potential - beatles.ru
Should you wait for a breakout in Immix Biopharma Inc.July 2025 Short Interest & AI Optimized Trade Strategies - Newser
Predicting Immix Biopharma Inc. trend using moving averages2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Sector ETF performance correlation with Immix Biopharma Inc.Weekly Investment Report & Fast Momentum Entry Tips - Newser
What high frequency data says about Immix Biopharma Inc.Market Risk Report & Low Risk High Win Rate Stock Picks - Newser
Quantitative breakdown of Immix Biopharma Inc. recent moveEarnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Immix Biopharma Inc. stock daily chart insightsLayoff News & Safe Entry Zone Tips - Newser
Key metrics from Immix Biopharma Inc.’s quarterly dataMarket Trend Summary & Daily Profit Maximizing Trade Tips - Newser
What’s the recovery path for long term holders of Immix Biopharma Inc.Bear Alert & Safe Entry Point Identification - Newser
Is Immix Biopharma Inc. building a consolidation base2025 Major Catalysts & Capital Efficiency Focused Strategies - Newser
Is Immix Biopharma Inc. stock bottoming outTrade Risk Report & AI Based Buy and Sell Signals - Newser
Is Immix Biopharma Inc. trending in predictive chart modelsExit Point & Momentum Based Trading Ideas - Newser
Visual analytics tools that track Immix Biopharma Inc. performanceExit Point & AI Powered Buy/Sell Recommendations - Newser
Published on: 2025-08-17 05:42:31 - metal.it
Analyzing Immix Biopharma Inc. with risk reward ratio chartsJuly 2025 Catalysts & Smart Allocation Stock Reports - Newser
Market reaction to Immix Biopharma Inc.’s recent newsMarket Performance Summary & Daily Entry Point Alerts - Newser
How moving averages guide Immix Biopharma Inc. tradingTrade Signal Summary & Intraday High Probability Alerts - Newser
Will Volume Confirm Reversal in Immix Biopharma Inc.2025 Growth vs Value & Free Fast Entry Momentum Trade Alerts - thegnnews.com
Why Immix Biopharma Inc. stock attracts strong analyst attentionQuarterly Market Summary & Capital Efficiency Focused Ideas - newsyoung.net
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):